SIHUAN PHARMA HLDGS GROUP LTD.

Full Company Name:	Sihuan Pharmaceutical Holdings Group Ltd
Incorporated in :	BERMUDA
Incorporated on :	26 Apr 2006
ISIN Code :	BMG8162K1053
Registered Office :	Canon’s Court 22 Victoria Street Hamilton HM 12 Bermuda
Telephone:	(86) 898 68556900
Fax:	(86) 898 68542333
Secretary:	Lim Mee Fun Lim Aik Kun
Link to Internet Website

SHARE CAPITAL
-
Authorised Capital :	USD12,000,000	Par Value :	USD0.020
Issued & Paid-up Capital :	USD9,400,000	Trading Currency :	SGD

LISTINGS Listed on 23 March 2007 on SGX Mainboard

REGISTRARS Reid Management Limited (Bermuda) Tricor Barbinder Share Registration Services (Singapore) REGISTRAR ADDRESS Reid Management Limited Argyle House 41a Cedar Avenue Hamilton HM12 Bermuda Tricor Barbinder Share Registration Services 8 Cross Street #11-00 PWC Building Singapore 048424

AUDITORS PricewaterhouseCoopers

BACKGROUND The Company was incorporated in Bermuda on 26 April 2006. Headquartered in Haikou, Hainan Province with manufacturing facilities located in Beijing, the Group is specialized in the field of cardiocerebral vascular drugs. The principal business activities can be categorised as follows: i) R&D, production and/or sale of cardiocerebral vascular drugs The Group’s cardiocerebral vascular drugs are used for the treatment of a wide range of cardiocerebral vascular diseases, such as coronary heart disease, pneumocardial disease, cerebrovascular disease, rheumatic fever, chronic rheumatic heart disease, atheroma, hypertension and embolism. ii) R&D, production and/or sale of non-cardiocerebral vascular drugs The non-cardiocerebral vascular drugs include those used for the treatment of cancer, infections caused by bacteria, refractory infections from tuberculosis, chronic respiratory diseases, prevention and treatment of chronic hepatitis and hepatic cirrhosis. As at January 2007, the Group markets and sells 13 cardiocerebral vascular drugs and 18 noncardiocerebral vascular drugs in different forms and dosages. Through its in-house R&D team in Haikou City, Hainan, and Beijing, as well as through joint collaborations with renowned third-party research institutions, academic bodies and pharmaceutical research companies, the Group is in the process of developing or procuring the development of more than 50 pharmaceutical products which are at various stages of development.

Information Last updated on 01/06/2009 07:01:11 AM